Citigroup Inc Igm Biosciences, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Citigroup Inc holds 10,965 shares of IGMS stock, worth $22,916. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,965

Previous 3,320 230.27%

Holding current value

$22,916

Previous $22,000 722.73%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$6.28 - $17.68 $48,010 - $135,163	7,645 Added 230.27%	10,965 $181,000
Q2 2024 Aug 12, 2024	BUY	$6.51 - $11.47 $5,181 - $9,130	796 Added 31.54%	3,320 $22,000
Q1 2024 May 10, 2024	BUY	$8.68 - $17.36 $5,529 - $11,058	637 Added 33.76%	2,524 $24,000
Q4 2023 Feb 09, 2024	BUY	$3.94 - $8.79 $5,713 - $12,745	1,450 Added 331.81%	1,887 $15,000
Q3 2023 Nov 09, 2023	SELL	$6.66 - $10.64 $26,273 - $41,974	-3,945 Reduced 90.03%	437 $3,000
Q2 2023 Aug 10, 2023	BUY	$8.86 - $14.0 $30,575 - $48,314	3,451 Added 370.68%	4,382 $40,000
Q1 2023 May 11, 2023	BUY	$13.74 - $25.76 $3,242 - $6,079	236 Added 33.96%	931 $12,000
Q4 2022 Feb 09, 2023	SELL	$15.45 - $26.02 $710 - $1,196	-46 Reduced 6.21%	695 $11,000
Q3 2022 Nov 10, 2022	SELL	$15.42 - $27.01 $8,851 - $15,503	-574 Reduced 43.65%	741 $17,000
Q2 2022 Aug 10, 2022	SELL	$13.27 - $25.5 $18,299 - $35,164	-1,379 Reduced 51.19%	1,315 $23,000
Q1 2022 May 12, 2022	SELL	$13.42 - $29.73 $559,184 - $1.24 Million	-41,668 Reduced 93.93%	2,694 $72,000
Q4 2021 Feb 10, 2022	BUY	$27.59 - $66.39 $663,180 - $1.6 Million	24,037 Added 118.26%	44,362 $1.3 Million
Q3 2021 Nov 10, 2021	BUY	$65.76 - $90.65 $1.34 Million - $1.84 Million	20,325 New	20,325 $1.34 Million

Others Institutions Holding IGMS

# of Institutions

Shares Held

20.7M

Call Options Held

68K

Put Options Held

52.2K

View Full List

About IGM Biosciences, Inc.

Ticker IGMS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,969,000
Market Cap $60.5M
Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...

More about IGMS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account